Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions MXN. Fiscal year is October - September.

Millions MXN. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Aug '25 Aug 11, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2016 - 2020
Market Capitalization	51,720	46,299	10,127	3,009	8,670	4,793	Upgrade
Market Cap Growth	-13.74%	357.17%	236.62%	-65.30%	80.91%	519.02%	Upgrade
Enterprise Value	66,215	44,047	10,062	3,344	8,224	4,746	Upgrade
Last Close Price	185.78	183.00	81.00	98.80	-	-	Upgrade
PS Ratio	4.34	6.24	3.45	1.14	10.77	21.65	Upgrade
PB Ratio	1.28	1.34	0.86	0.37	1.38	13.22	Upgrade
P/TBV Ratio	1.36	1.35	0.88	0.38	1.48	87.00	Upgrade
P/FCF Ratio	-	-	-	2.77	-	-	Upgrade
P/OCF Ratio	-	-	-	2.04	-	-	Upgrade
EV/Sales Ratio	5.65	5.94	3.43	1.27	10.21	21.43	Upgrade
EV/EBITDA Ratio	6.45	10.77	-	7.29	-	-	Upgrade
EV/EBIT Ratio	13.65	41.52	-	-	-	-	Upgrade
EV/FCF Ratio	-6.15	-	-	3.07	-	-	Upgrade
Debt / Equity Ratio	0.38	0.04	0.02	0.06	0.01	0.04	Upgrade
Debt / EBITDA Ratio	1.48	0.32	-	0.97	-	-	Upgrade
Debt / FCF Ratio	-	-	-	0.41	-	-	Upgrade
Asset Turnover	0.28	0.28	0.28	0.34	0.23	0.44	Upgrade
Inventory Turnover	-	-	-	278.79	32.16	-	Upgrade
Quick Ratio	0.14	0.66	0.53	0.62	1.59	0.96	Upgrade
Current Ratio	4.37	3.76	1.38	1.49	5.74	1.53	Upgrade
Return on Equity (ROE)	17.09%	-11.97%	-24.77%	-11.30%	-5.11%	-132.23%	Upgrade
Return on Assets (ROA)	7.14%	2.49%	-12.90%	-4.25%	-4.38%	-41.35%	Upgrade
Return on Capital (ROIC)	7.46%	2.69%	-14.01%	-4.47%	-4.59%	-48.54%	Upgrade
Return on Capital Employed (ROCE)	9.30%	3.10%	-	-	-	-	Upgrade
Earnings Yield	10.66%	-6.17%	-23.75%	-38.28%	-5.16%	-10.75%	Upgrade
FCF Yield	-20.82%	-12.68%	-13.53%	36.17%	-38.59%	-3.08%	Upgrade
Buyback Yield / Dilution	-55.90%	-111.14%	-141.02%	-44.74%	-208.27%	-128.63%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.